Work

Phase III randomized trial of volasertib combined with low-dose cytarabine (LDAC) versus placebo plus LDAC in patients aged ≥65 years with previously untreated, acute myeloid leukemia (AML) ineligible for intensive remission induction therapy

Year: 2015

Type: article

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/j.clml.2015.04.046

Authors: Daniel J. DeAngelo, Mikkael A. Sekeres, Oliver G. Ottmann, Miguel A. Sanz, Tomoki Naoe, Tillmann Taube, Valerie Belsack, Miaomiao Ge, Hartmut Döhner

Institutions: Dana-Farber Cancer Institute, Cleveland Clinic, Goethe University Frankfurt, Hospital Universitari i Politècnic La Fe, Nagoya Medical Center, Boehringer Ingelheim (Germany), Boehringer Ingelheim (Belgium), Boehringer Ingelheim (United States), University Hospital Ulm

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2223451583

FWCI: 1.045

Cites:

Cited by: 9

Related to: 10